Bayer discussing combo products
This article was originally published in The Tan Sheet
Executive Summary
Bayer HealthCare has responded to inquiries from FDA and the House Energy and Commerce Committee regarding the firm's OTC combination products, Anne Coiley, director of Bayer's global cardio communications in its consumer care division, says Nov. 18. FDA "has been in discussions with Bayer" and the "matter remains an open investigation," an FDA spokesperson confirms Nov. 19. Bayer received a letter from the House committee in October, followed by FDA warning letters on its products Bayer Aspirin With Heart Advantage,which adds phytosterols to aspirin, and Bayer Women's Low Dose Aspirin + Calcium. FDA's Oct. 27 warning letter notes the combo productsare technically unapproved new drugs (1"The Tan Sheet" Nov. 3, 2008, p. 9)
You may also be interested in...
Bayer Warning Letters Reinforce FDA Ban On Supplement/Drug Combinations
FDA warns Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.